Use of okadaic acid in preparation of medicine for resisting glaucoma operation scar

A technology of octamic acid and glaucoma, which is applied in the field of octamic acid in the pharmaceutical field, and can solve problems such as the proliferation of conjunctival sac fibroblasts that have not yet been seen

Inactive Publication Date: 2006-07-12
陈凤华
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is still no effective method to prevent or inhibit the proliferation of human conjunctival sac fibroblasts

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0095] The octamic acid can be combined with pharmaceutically acceptable auxiliary materials to make corresponding dosage forms for clinical use. A preferred preparation method is to dissolve octamic acid in distilled water, or physiological saline, or phosphate buffer saline for use. The optimal concentration of octamic acid is 50-200nmol / L. It is used for local application or spraying on the filtering bleb during glaucoma filtering bleb surgery, and it can also be used for eye drops in the early stage (within two weeks) after the operation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of the phosphatase inhibitor Okadaic acid, OA in preparing drug used to prevent partial fibrosis and cicatrisation after the glaucoma folliculus operation, preparing medical composite with effect amount Okadaic acid, OA with medical findings, employing water, normal saline or phosphate buffer solution as solvent, with the proper concentration being 50-200 nmol/l, daubing or spraying the product on the folliculus part, or eye dropping before operation (two weeks).

Description

technical field [0001] The present invention relates to the application of okadaic acid (OA) in pharmaceuticals, specifically, the application of the medicine for preventing the scarring of the filtration bleb after the glaucoma filtration operation and improving the success rate of the operation. Background technique [0002] The English abbreviations used in this specification represent several chemical substances respectively, and their corresponding relations are as follows: [0003] MMC Mitomycin C (Mitomycin C) MTT tetramethyl azozolium salt [0004] SDS Sodium Lauryl Sulfate DMF Dimethylformamide [0005] FN fibronectin (extracellular matrix protein, fibronectin) [0006] PBS phosphate buffer solution BSA bovine serum albumin OD value absorbance value [0007] Filtration surgery is the mainstay of treatment for patients with glaucoma that cannot be controlled by medication. The progress of wound healing after glaucoma filtration is related to the success or failur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/35A61P27/02A61P27/06
Inventor 陈凤华庞文跃王津津李志辉王宁利
Owner 陈凤华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products